nach oben

Erschienen in:

01.04.2015 | Comment

Metformin in patients with renal disease: restrictive guidelines?

Erschienen in: Reactions Weekly | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Excerpt

Despite a recent labelling update¹ approved by the UK MHRA allowing use of the antidiabetic agent metformin (Glucophage) in patients with renal disease, there is still a concern that generic metformin − which is contraindicated in patients with renal failure or renal dysfunction − "is too conservative and will deny an important drug to many thousands of people with diabetes who are likely to benefit from its important clinical effects and have few alternative treatments", according to members of the Departments of Diabetes and Nephrology at Barts and The London School of Medicine and Dentistry in the UK. …

The updated Summary of Product Characteristics for Glucophage now states that "Metformin may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45-59 mL/min or estimated glomerular filtration rate [eGFR] 45-59 mL/min/1.73 m ²) only in the absence of other conditions that may increase the risk of lactic acidosis" and also that "If CrCl or eGFR fall <45 mL/min or <45 mL/min/1.73 m ² respectively, metformin must be discontinued immedia tely".

Chowdhury TA, et al. Using metformin in the presence of renal disease. BMJ 350: [2 pages], 14 Apr 2015. Available from: URL: http://dx.doi.org/10.1136/bmj.h1758

Titel: Metformin in patients with renal disease: restrictive guidelines?
Publikationsdatum: 01.04.2015
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2015
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-015-9830-7

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Metformin in patients with renal disease: restrictive guidelines?

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Zolpidem

Cisplatin/docetaxel

Escitalopram

Lamotrigine/valproic acid interaction

Heparin

Posaconazole/zoriconazole